Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (271-280 of 377) with videos related to

Pageof 38
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2011
The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configurationMichael Souvatzoglou, Gregor Weirich, Sarah Schwarzenboeck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 18, 2017
Simultaneous whole-body <sup>18</sup>F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot studyMartin T Freitag, Claudia Kesch, Jens Cardinale, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 3, 2017
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingSara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerAndrei Gafita, Loic Djaileb, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2018
Detection Threshold and Reproducibility of <sup>68</sup>Ga-PSMA11 PET/CT in a Mouse Model of Prostate CancerKatharina Lückerath, Andreea D Stuparu, Liu Wei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [<sup>18</sup>F]PSMA-1007 PET/CT and [<sup>18</sup>F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient ManagementKaren M Buch-Olsen, Mie H Vilstrup, Steinbjørn Hansen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2024
<sup>61</sup>Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human ImagingTais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, et al.
Molecular Therapy Oncolytics|September 13, 2023
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing miceCarolin Kitzberger, Khuram Shehzad, Volker Morath, et al.
European Urology|December 9, 2020
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMABenedikt Feuerecker, Robert Tauber, Karina Knorr, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Markus Essler, Kim M Pabst, et al.
Pageof 38

Showing results (271-280 of 377) with videos related to

Sort By:
Pageof 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2011
The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configurationMichael Souvatzoglou, Gregor Weirich, Sarah Schwarzenboeck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 18, 2017
Simultaneous whole-body <sup>18</sup>F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot studyMartin T Freitag, Claudia Kesch, Jens Cardinale, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 3, 2017
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingSara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerAndrei Gafita, Loic Djaileb, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2018
Detection Threshold and Reproducibility of <sup>68</sup>Ga-PSMA11 PET/CT in a Mouse Model of Prostate CancerKatharina Lückerath, Andreea D Stuparu, Liu Wei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [<sup>18</sup>F]PSMA-1007 PET/CT and [<sup>18</sup>F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient ManagementKaren M Buch-Olsen, Mie H Vilstrup, Steinbjørn Hansen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2024
<sup>61</sup>Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human ImagingTais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, et al.
Molecular Therapy Oncolytics|September 13, 2023
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing miceCarolin Kitzberger, Khuram Shehzad, Volker Morath, et al.
European Urology|December 9, 2020
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMABenedikt Feuerecker, Robert Tauber, Karina Knorr, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Markus Essler, Kim M Pabst, et al.
Pageof 38